Prospective, single-center, and exploratory study of temozolomide and rituximab for relapsed/refractory central nervous system lymphoma.

Prospective, single-center, and exploratory study of temozolomide and rituximab for relapsed/refractory central nervous system lymphoma. - Temozolomide and rituximab for relapsed/refractory central nervous system lymphoma.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012730

Enrollment

Registered

2014-01-06

Start date

2014-01-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed/refractory central nervous system lymphoma

Interventions

Treatment with temozolomide and rituximab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with relapsed/refractory central nervous system lymphoma carrying a measurable lesion on brain MRI. 2. High-dose methotrexate and high-dose cytarabine are ineffective or intolerable. 3. Absolute neutrophil count >= 1*10^9 /L. 4. Platelet count >= 50*10^9 /L. 5. Tumor cells express CD20.

Exclusion criteria

Exclusion criteria: 1. Presence of uncontrollable infection. 2. Positive for serum anti-HIV antibody. 3. Positive for serum anti-HBV antigen or elevated serum HBV-DNA level.

Design outcomes

Primary

Measure	Time frame
Overall response rate and complete response rate.	—

Secondary

Measure	Time frame
Overall survival, and progression-free survival.	—

Countries

Japan

Contacts

Public ContactFumihiko Nakamura, MD, PhD

The University of Tokyo Hospital Department of Hematology and Oncology

fnakamur-tky@umin.ac.jp+81-3-5800-8741

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026